HDAC inhibitors was suggested as a therapeutic strategy for NUP98-fusion AML patients39; however, the NUP98-fusion events are restricted in the blood lineage for these patients, and normal NUP98 function is expected in other somatic tissues. The gene discussed is HDAC9; the disease is acute myeloid leukemia.